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OBJECTIVES: Proper assessment of dyspnea is important in patients with heart failure. Our aim was to evaluate
the use of the 5-point Likert scale for dyspnea to assess the degree of pulmonary congestion and to determine
the prognostic value of this scale for predicting adverse events in heart failure outpatients.
METHODS:We undertook a prospective study of outpatients with moderate to severe heart failure. The 5-point
Likert scale was applied during regular outpatient visits, along with clinical assessments. Lung ultrasound with
$15 B-lines and an amino-terminal portion of pro-B-type natriuretic peptide (NT-proBNP) level .1000 pg/mL
were used as a reference for pulmonary congestion. The patients were then assessed every 30 days during
follow-up to identify adverse clinical outcomes.
RESULTS: We included 58 patients (65.5% male, age 43.5¡11 years) with a mean left ventricular ejection
fraction of 27¡6%. In total, 29.3% of these patients had heart failure with ischemic etiology. Additionally,
pulmonary congestion, as diagnosed by lung ultrasound, was present in 58% of patients. A higher degree of
dyspnea (3 or 4 points on the 5-point Likert scale) was significantly correlated with a higher number of B-lines
(p=0.016). Patients stratified into Likert = 3-4 were at increased risk of admission compared with those in class
1-2 after adjusting for age, left ventricular ejection fraction, New York Heart Association functional class and
levels of NT-proBNP .1000 pg/mL (HR=4.9, 95% CI 1.33-18.64, p=0.017).
CONCLUSION: In our series, higher baseline scores on the 5-point Likert scale were related to pulmonary
congestion and were independently associated with adverse events during follow-up. This simple clinical tool
can help to identify patients who are more likely to decompensate and whose treatment should be intensified.
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& INTRODUCTION
Dyspnea is defined as the subjective experience of
breathing discomfort that consists of qualitatively distinct
sensations that vary in intensity. This condition is caused by
interactions among multiple physiological, psychological,
social and environmental factors and may induce secondary
physiological and behavioral responses (1). The objective
quantification of dyspnea in heart failure (HF) patients is
limited by the subjective reporting of this common
symptom. Moreover, there is no consensus regarding the
best way to measure and quantify the subjective sensation of
‘‘shortness of breath’’, making this task extremely difficult
for patients and healthcare professionals (2).
The 5-point Likert scale (5PLS) for dyspnea is a psycho-
metric instrument for the measurement and grading of
dyspnea (1,3,4). Certain authors recommend the use of this
scale to assess patients with acute decompensated HF (5-7).
Others state that the best way to measure dyspnea involves
evaluating quality of life; however, the questionnaires used
for this type of assessment are lengthy and require more
experienced and well-trained researchers. Thus, such ques-
tionnaires are usually not well suited for daily clinical
practice. Taken together, these issues justify the use of
simpler instruments to properly grade dyspnea (8-10).
Lung ultrasound (LUS) through B-line evaluation (for-
merly referred to as ultrasound lung comets) has been
proposed as a simple, noninvasive and semiquantitative
tool for the assessment of extravascular lung water (11,12).
A recent study (13) of chronic HF outpatients demonstrated
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the reliability of this noninvasive method in identifying
clinically silent pulmonary edema and predicting adverse
outcomes (14). In HF, the amino-terminal portion of pro-
B-type natriuretic peptide (NT-proBNP) is a powerful
neurohormonal predictor of prognosis and elevated left
ventricular (LV) filling pressures, and higher levels are
correlated with greater degrees of pulmonary congestion
(15-17).
To date, no study has evaluated the intensity of dyspnea
quantified by 5PLS for the estimation of significant
pulmonary congestion (SPC) in chronic HF outpatients
(18). The aim of this study was to determine whether
dyspnea graded using a 5PLS can be used to objectively
define SPC and predict the occurrence of adverse events
in chronic HF outpatients, in comparison with the use of
LUS, NT-proBNP levels and New York Heart Association
(NYHA) functional class.
& MATERIALS AND METHODS
Study design and population
Single-center cross-sectional study followed by cohort
study of 58 patients with systolic HF who were followed at a
pre-transplant outpatient clinic at the Cardiology Institute of
Rio Grande do Sul, Brazil, between November 2011 and
January 2012. The inclusion criteria were as follows: 1) age
.18 years; 2) a diagnosis of LV systolic HF for more than 6
months, regardless of the cause, as defined by the
Framingham criteria (19) and satisfying the European
Society of Cardiology’s guidelines (20); 3) moderate to
severe systolic HF (ejection fraction (EF) ,45%); 4) no prior
diagnosis of pulmonary fibrosis,; 5) the absence of con-
genital heart disease; and 6) no recent admission due to
decompensated HF in the previous 6 months.
Clinical assessment, NT-proBNP analysis, LUS, echocar-
diography and chest X-ray (CXR) were independently
performed by different physicians at the first clinical
appointment (index evaluation), with a maximum 5-hour
time delay between the first and last examinations.
Following a brief explanation provided by a nurse, all
patients filled out a 5PLS immediately before and after
undergoing a 6-minute walk test (6MWT) in accordance
with standardized methodology.
The 5PLS for dyspnea
The 5PLS for dyspnea is a self-administered psychometric
instrument for measuring and grading the experience of
breathing discomfort that has been validated for use in
acute decompensated HF patients (1-4). This scale can be
used to verify changes in the intensity of shortness of breath
between two different time points. The scale includes the
absence of dyspnea (a score of 1), mild shortness of breath (a
score of 2), moderate shortness of breath (a score of 3),
severe shortness of breath (a score of 4) and the worst
possible shortness of breath (a score of 5). All patients filled
out the 5PLS without any interference after a brief
explanation provided by a nurse.
LUS, NT-proBNP measurement and clinical
assessment
LUS was used to assess the presence of B-lines (12,21). A
B-line was defined as a discrete laser-like vertical hyper-
echoic reverberation artifact that arises from the pleural line,
extends to the bottom of the screen without fading and
moves synchronously with lung sliding (22). We analyzed
the anterior and lateral hemithoraces, scanning along the
parasternal, midclavicular, anterior axillary and mid-axil-
lary lines, as previously described (22). A total of 28 chest
sites were scanned, and the total number of B-lines was
recorded by an independent investigator. A B-line number
$15 was considered as the cut-off for SPC (13).
An NT-proBNP analysis was performed using the
ElecsysH 2010 analyzer (Roche Diagnostics, Mannheim,
Germany). An NT-proBNP level .1000 pg/mL was used
as the cut-off for decompensated HF (17,23).
Statistical analysis
Continuous variables are expressed as the mean ¡
standard deviation or as the median (25th-75th percentiles),
as appropriate. We used Student’s t-test for continuous
variables with symmetric distribution and the chi-square
test or Fisher’s exact test for categorical variables. For
asymmetrical variables, the Mann-Whitney test and
ANOVA were used for repeated measures. The correlation
between the 5PLS score and the number of B-lines was
assessed using non-parametric Spearman’s correlation
analysis. Additionally, multivariate analysis was used to
verify the differences between the different 5PLS scores, and
logistic regression models were employed. First, separate
analyses were performed for individual variables to allow
for the largest possible sample size. Second, stepwise
models were run using all of the potential risk factors
identified in the univariate analysis. Finally, a model was
run using a backward stepwise (likelihood) method that
included variables meeting the following entry criteria: a p-
value of 0.05 and a removal value of 0.20 in the prior
regression analysis. A two-tailed p-value ,0.05 was con-
sidered to be statistically significant. The cumulative
incidence of hospital admission during follow-up was
analyzed individually and collectively using the Cox
proportional hazard regression model. Kaplan-Meier survi-
val analysis with the log-rank test was also used. All
statistical analyses were performed using IBM SPSS
Statistics version 19.0.0 (Chicago, IL, USA).
Ethics
The study protocol was approved by the ethics committee
of our institution (protocol 4720/12). All of the participants
provided informed consent, and the study complied with
the Declaration of Helsinki.
& RESULTS
The main characteristics of the patients are listed in
Table 1. The mean age was 49¡11 years, and 47.2% of the
patients had idiopathic dilated cardiomyopathy. The mean
LV EF, as determined by the bi-planar Simpson method,
was 27¡4%, and the left atrial volume indexed to body
surface area was 53.8¡27 mL/m2. The patients were
followed up for a median period of 106¡12 days (inter-
quartile range: 89-115 days).
SPC was diagnosed in 44.8% of subjects, based on an NT-
proBNP level .1,000 pg/mL. In total, 58% of patients had
SPC, as diagnosed by LUS ($15 B-lines).
When the 5PLS for dyspnea was applied during rest,
44.8% of patients had a score of 1, 32.7% had a score of 2,
17.2% had a score of 3, and 5.17% had a score of 4. None of
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the patients had a score of 5 points on the scale when it was
administered during rest.
The mean NYHA functional class was higher for those
patients who had higher scores on the 5PLS for dyspnea
(p,0.001). The mean NYHA functional class was 3.67 for
Likert = 4, 3 for Likert = 3, 2 for Likert = 2 and 1.87 for
Likert = 1. There were no significant differences in mean NT-
proBNP levels between groups with different perceptions of
dyspnea (p= 0.16). After the 6MWT, there was a significant
increase in the mean score on the 5PLS for dyspnea
compared with the mean score at rest (p,0.0001) (Figure 1).
When separated based on their score on the 5PLS for
dyspnea, patients who had a score of 4 had more B-lines
identified by LUS than in the other groups (p= 0.016)
(Figure 2).
Adverse events occurred in 15 patients during follow-up.
Twelve of the patients were hospitalized with pulmonary
congestion. In addition, two were hospitalized with acute
myocardial infarction (AMI), and one experienced an
implantable cardiac defibrillator (ICD) shock due to
ventricular tachycardia.
Adverse event-free survival was higher in patients with
lower scores on the 5PLS for dyspnea (log-rank p,0.001).
Patients with Likert scores of 3 or 4 were at higher risk of
emergency room admission during follow-up than were
those with scores of 1 or 2 after adjusting for factors such as
age, LV EF, NYHA functional class and levels of NT-
proBNP .1000 pg/mL (HR=4.9, 95% CI 1.33-18.64,
p= 0.017) (Figure 3).
& DISCUSSION
Our results demonstrate that there is an objective
relationship between the score on the 5PLS for dyspnea,
which assesses the severity of symptoms perceived by the
patient, and higher levels of extravascular lung water, as
assessed based on LUS and elevated LV filling pressure and
NT-proBNP levels. However, a previous study that inves-
tigated the relationships between patient history, physical
examination results, CXR findings and pulmonary capillary
pressure in 42 patients with HF who were referred for
assessment for a heart transplant showed that the clinical, X-
ray and hemodynamic assessments failed because they
Table 1 - Primary patient characteristics.
Characteristic N=58 (%)
Age 49¡11
Caucasian 46 (79)
Male 38 (65)
Body mass index 28¡4
Heart rate (beats per minute) 74¡12
Systolic arterial pressure (mmHg) 112¡17
Diastolic arterial pressure (mmHg) 71¡11
Coronary artery disease 16 (27)
Myocardial infarction 15 (26)
Hypertension 24 (41)
Dyslipidemia 26 (49)
COPD 1 (2)
Diabetes mellitus 12 (20)
Minnesota score 43¡22
Cardiomyopathy etiolog
Idiopathic 29 (50)
Post-ischemic 17 (29)
Hypertension 6 (10)
Myocarditis 4 (7)
Other 2 (4)
NYHA functional class
I 15 (26)
II 24 (41)
III 13 (23)
IV 6 (10)
Left ventricular ejection fraction () 27¡0.9
Left atrial volume (mL/m2) 54¡27
Electrocardiogra
Sinus rhythm 46 (79)
Atrial fibrillation 10 (17)
Pace 2 (3)
QRS $150 ms 35 (60)
Creatinine/CC 0.9¡0.3/109¡40
Chronic renal failure 7 (12)
Urea (mg/dL) 48¡27
Potassium (meq/L) 4.4¡0.5
Sodium (meq/L) 139¡4
Hematocrit ()/Hemoglobin (g/dL) 40¡4/13¡1.4
b-blocker 56 (96)
Target dose 22 (38)
ACE inhibitor 38 (65)
Target dose 12 (20)
Angiotensin II receptor blocker 15 (26)
Target dose 9 (15)
Aldosterone antagonist 42 (72)
Diuretics 42 (72)
Digoxin 34 (58)
Calcium antagonists 3 (5)
Nitrates 10 (17)
Hydralazine 4 (0.7)
Statin 27 (46)
Aspirin 24 (41)
Coumarin 10 (17)
Amiodarone 8 (14)
Pace/ICD 9 (15)
CRT 4 (7)
The data are presented as the mean ¡ standard deviation or n().
ACE: Angiotensin-converting enzyme; CC: Creatinine clearance; COPD:
Chronic obstructive pulmonary disease; CRT: Cardiac resynchronization
therapy; ICD: Implantable cardiac defibrillator; NYHA: New York Heart
Association.
Figure 1 - Five-point Likert scale for dyspnea before and after
effort.
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Figure 2 - Number of B-lines estimated by lung ultrasound in patients with different dyspnea scores measured by the 5-point Likert
scale for dyspnea. ANOVA: p=0.016. The Student-Newman-Keuls test for all pairwise comparisons revealed a difference between those
patients who had a score of 4 on the 5-point Likert scale for dyspnea and those with other scores (p,0.05).
Figure 3 - Kaplan-Meier 1-cumulative survival curve for the emergency room admission of patients stratified into two groups based on
the 5-point Likert scale for dyspnea: patients with scores of 1-2 and patients with scores of 3-4.
Quantifying dyspnea
Weber CK et al.
CLINICS 2014;69(5):341-346
344
yielded conflicting results (19). These authors justified this
conclusion based on the fact that patients with an elevated
pulmonary capillary pressure may show no congestion
during a clinical or radiological exam, and the absence
of congestion on an X-ray is associated with a better
pulmonary capacity. This discordance among clinical,
radiological and hemodynamic results has implications
for the management of patients with HF and could lead
to inaccurate diagnoses and inadequate treatment (24).
Echocardiography can also be used to noninvasively
measure LV filling pressures (12); the ratio of the early
diastolic mitral inflow velocity to the early diastolic velocity
of the mitral annulus (E/e’) is one of the most frequently
used parameters for the assessment of LV pressures (13,14).
Both natriuretic peptides and E/e’ can be used to identify
hemodynamic congestion in systolic and diastolic HF
patients, a condition that precedes pulmonary congestion.
Furthermore, pulmonary congestion is usually, but not
always, related to high LV filling pressure, which may
explain the absence of a correlation with NT-proBNP levels
(25).
HF causes functional, metabolic and histological changes
in the inspiratory muscles. In 30-50% of patients, these
muscles are weak, with a consequent reduction in functional
capacity, a worse clinical prognosis and a lower quality of
life for these individuals. Furthermore, there is a relation-
ship between the autonomic control systems of these
patients and intolerance to exercise, in addition to weakness
of the inspiratory muscles, which, according to previously
performed studies, can be improved with physical training
(25). This phenomenon plays an important role in the
sensation of shortness of breath during and after exercise.
We believe that the 5PLS can transform the sensation of
dyspnea (subjective data) into objective data because in our
patient population, we were able to demonstrate an
excellent relationship between the Likert scores and the
pulmonary ultrasound findings used to quantify the
amount of free fluid in the lungs of this cohort of patients
with advanced HF. However, this relationship was not
observed when the scale was used after exercise. This
finding may be due to the muscle component of dyspnea,
which plays a major role in the chronically ill patient
population, especially after physical activity. Thus, the
severity of dyspnea measured by the Likert scale is only
directly correlated with pulmonary congestion when used
to assess patients at rest.
Perhaps the most striking finding of our study is that
patients who had grade 3 or 4 dyspnea (defined by the 5PLS
for dyspnea as moderate and strong, respectively) had a
greater number of hospital admissions. This correlation
remained statistically significant even after controlling for
clinical factors that are already known to predict adverse
outcomes, such as the NYHA functional class, the EF and
NT-proBNP levels. In our view, dyspnea must be measured
objectively when obtaining a patient’s history during the
initial clinical exam because dyspnea is the most common
and significant symptom of distress in patients with HF.
This symptom is still an important therapeutic target, and
its measurement should influence treatment (7,8). Despite
the reduced number of patients receiving the target dose of
HF medication, similar to what has been reported in the
literature, no relationship was found with the occurrence of
adverse events.
Another important observation is that that the Likert scale
can even help to distinguish patients who are in the same
functional class (e.g., NYHA III) by objectively grading
the intensity of dyspnea at the same level of effort. This
distinction can independently predict clinical outcomes
during follow-up, as demonstrated by multivariate analysis.
Patients with HF generally present signs and symptoms
of pulmonary systemic congestion when they are admitted
to the hospital. However, high LV filling pressures may be
present long before the development of clinical pulmonary
congestion that results in hospital admission. Thus, it is
necessary to manage and reassess pulmonary and systemic
congestion at each clinical encounter (26).
The 5PLS for dyspnea used in this study is easy to apply
and can be used by any healthcare professional (e.g., nurses,
physicians, physician’s assistants and respiratory therapists)
in HF outpatient clinics. This simple score for the assess-
ment of dyspnea has an objective correlation with pulmon-
ary congestion and has prognostic implications.
One limitation of this study is the small size of the sample,
which included only patients with moderate to severe
systolic dysfunction. This limitation should be taken into
account when interpreting the results. Moreover, the lack
of a gold standard to verify the presence or absence of
pulmonary congestion in the outpatient environment is a
further limitation of the study. However, the utilization of
the NT-proBNP level and the E/e’ relationship, rather than
invasive measures, made it possible to perform the study
during routine outpatient visits with patients in a stable
clinical condition. Additionally, the change in the 5PLS
score after the 6MWT was not tested in comparison with
other methodologies to determine whether the score was
correlated with increased extravascular lung water after the
exercise test.
In our cohort of HF patients, the 5PLS for dyspnea was
able to predict adverse clinical events, even when control-
ling for potential biases (NYHA functional class, EF, age and
NT-proBNP levels). Higher scores on the 5PLS for dyspnea
were associated with unfavorable clinical outcomes in
patients with HF. The scale was also capable of quantifying
pulmonary congestion objectively. Healthcare professionals
can use this instrument to better assess patients and
improve their care, thereby potentially reducing the rate of
hospital admissions.
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